Multimodality molecular imaging of the lung.

Area of Science:

• Multimodal imaging
• Molecular imaging
• Pulmonary medicine

Background:

• Lung diseases contribute significantly to morbidity, mortality, and healthcare costs.
• Limited availability of specific biomarkers hinders accurate disease monitoring and drug development.
• Current diagnostic tools often lack the sensitivity for precise molecular assessment.

Purpose of the Study:

• To review the fundamental physics of positron emission tomography (PET), single-photon emission computed tomography (SPECT), computed tomography (CT), and magnetic resonance (MR) lung imaging.
• To discuss technical challenges and considerations for multimodal lung imaging quantification, particularly for PET and SPECT.
• To explore current and potential clinical applications of hybrid imaging technologies in lung disease management.

Main Methods:

• Review of basic physics principles for PET, SPECT, CT, and MR imaging in the context of lung applications.
• Analysis of technical challenges in lung imaging, including low tissue density and respiratory motion.
• Examination of quantification strategies for hybrid PET and SPECT imaging in multimodal setups.

Main Results:

• Hybrid imaging technologies (e.g., PET-MR, SPECT-CT) show promise for developing noninvasive, molecular biomarkers for lung disease.
• Addressing challenges like lung density and motion is crucial for accurate data quantification in multimodal lung imaging.
• These advanced imaging techniques have emerging and potential clinical roles in diagnosing and managing lung conditions.

Conclusions:

• Multimodal imaging approaches, integrating PET, SPECT, CT, and MR, are advancing the development of novel lung disease biomarkers.
• Overcoming technical hurdles in lung imaging quantification is key to realizing the full potential of these hybrid systems.
• Hybrid imaging offers a pathway to improved clinical management and accelerated drug development for pulmonary diseases.